ZIDCEF-250
Description
- Contains Ceftazidime 250 mg, a third-generation cephalosporin
- Broad-spectrum antibacterial activity against Gram-negative and some Gram-positive organisms
- Highly effective in treating respiratory, urinary, abdominal, and skin infections
- Bactericidal mechanism: inhibits bacterial cell wall synthesis
- Active against resistant strains, including Pseudomonas species
- May be used in both pediatric and adult patients (dose adjusted accordingly)
- Should be taken under healthcare supervision to prevent resistance
Composition
CEFTAZIDIME-250 MG,
Benefits
ZIDCEF-250 offers several therapeutic advantages, particularly in the treatment of infections caused by resistant or hospital-acquired pathogens. Its high potency against Gram-negative bacteria, including Pseudomonas aeruginosa, makes it highly effective in respiratory, urinary, and soft tissue infections. Ceftazidime’s strong bactericidal action ensures rapid symptom relief, reduced inflammation, and lower risk of complications. ZIDCEF-250 is also well-tolerated and suitable for step-down therapy in patients transitioning from injectable antibiotics to oral treatment under medical supervision.
Introduction
ZIDCEF-250 is a broad-spectrum antibiotic containing Ceftazidime 250 mg, a third-generation cephalosporin known for its potent activity against a wide range of Gram-negative and some Gram-positive bacteria. It acts by inhibiting bacterial cell wall synthesis, leading to effective bacterial elimination. ZIDCEF-250 is indicated for the treatment of moderate to severe bacterial infections such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and abdominal infections. Its robust efficacy and broad antimicrobial coverage make it a preferred choice in managing complicated infections in both children and adults, depending on the dosage form.
